Linker Information
General Information of This Linker
| Linker ID |
LIN0ELNZK
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Mc-Val-Ala-PABC double self-immolative linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C29H41N5O9S
|
|||||
| Isosmiles |
CC(C)[C@H](NC(=O)CCCCCN1C(=O)C=CC1=O)C(=O)N[C@@H](C)C(=O)Nc1ccc(COC(=O)NCCS(C)(=O)=O)cc1
|
|||||
| InChI |
InChI=1S/C29H41N5O9S/c1-19(2)26(33-23(35)8-6-5-7-16-34-24(36)13-14-25(34)37)28(39)31-20(3)27(38)32-22-11-9-21(10-12-22)18-43-29(40)30-15-17-44(4,41)42/h9-14,19-20,26H,5-8,15-18H2,1-4H3,(H,30,40)(H,31,39)(H,32,38)(H,33,35)/t20-,26-/m0/s1
|
|||||
| InChIKey |
RVUSUWGWXJLYOV-FNZWTVRRSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
635.74
|
Polar area
|
197.15
|
||
|
Complexity
|
635.2624989
|
xlogp Value
|
1.0268
|
|||
|
Heavy Count
|
44
|
Rot Bonds
|
17
|
|||
|
Hbond acc
|
9
|
Hbond Donor
|
4
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
FDA-022 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05564858 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA022-BB05 in subjects with advanced solid malignant tumors.
|
||||
References